Rademikibart单药治疗中重度特应性皮炎:1年随机II期试验(SEASIDE CHINA)
SEASIDE CHINA是一项在中国中重度特应性皮炎患者中开展的1年随机II期试验,评估rademikibart(CBP-201)的疗效与安全性。第1阶段16周双盲对照显示,rademikibart组达到vIGA 0/1且较基线下降≥2分的患者比例为29.0%,显著高于安慰剂组的5.9%(P<0.001)。第2阶段至52周,Q2W与Q4W给药均维持或进一步改善疗效,且耐受性良好。
要点
- Rademikibart Q2W在16周时vIGA 0/1应答率29.0%,安慰剂5.9%(P<0.001)。
- 52周时Q2W与Q4W给药疗效相似,vIGA应答率分别为59.1%和62.6%。
- 注射部位反应均为1级(轻度),无治疗相关严重TEAEs。
核心结论
- Rademikibart Q2W在初始16周诱导AD皮损和瘙痒快速改善,并在额外36周内以Q2W或Q4W给药维持或进一步改善。
- Rademikibart Q2W与Q4W疗效相似且耐受性良好。
研究设计与样本
- SEASIDE CHINA(NCT05017480)为II期随机试验,共随机330例中国中重度AD成人/青少年患者,2:1双盲分配至rademikibart或安慰剂。
- 第1阶段为16周治疗期,第2阶段包括36周治疗和8周随访期。
- 第1阶段给药方案:第1天皮下注射rademikibart 600 mg,第2-14周300 mg Q2W;第16周前评估EASI 50后,1:1双盲重随机至rademikibart 300 mg Q2W或Q4W。
主要发现
- 第1阶段第16周,rademikibart Q2W组29.0%达到vIGA 0/1且较基线下降≥2分,安慰剂组5.9%(P<0.001)。
- 第16周EASI 75应答率rademikibart Q2W组58.6%,安慰剂组22.6%;PP-NRS下降≥4分比例分别为36.3%和10.5%。
- 第2阶段第52周,第16周EASI 50应答者继续治疗,vIGA应答率Q2W 59.1%、Q4W 62.6%;EASI 75分别为84.6%和84.8%;PP-NRS下降≥4分分别为60.4%和70.3%。
- 第16周Q2W治疗有改善的患者中,第52周维持应答:vIGA Q2W 78.0%、Q4W 87.1%;EASI 75 Q2W 90.1%、Q4W 92.3%;PP-NRS下降≥4分Q2W 85.3%、Q4W 94.8%。
临床怎么用
- Rademikibart Q2W可快速改善中重度AD患者的皮损和瘙痒,Q4W给药在长期维持治疗中疗效相似且可能提高便利性。
- 治疗期间注射部位反应多为轻度,但需监测AD flare、白癜风等不良事件,妊娠者需停药。
局限性
- 原文指出需要更大规模的临床试验进一步研究rademikibart。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rademikibart (CBP-201) is a potent, next-generation human monoclonal antibody optimized to bind with high affinity to interleukin-4 receptor subunit alpha. OBJECTIVES: To evaluate rademikibart efficacy and safety, initially dosed every other week (Q2W), and Q2W or every fourth week (Q4W) from week 16, in Chinese adults/adolescents with moderate-to-severe atopic dermatitis (AD). METHODS: SEASIDE CHINA (NCT05017480) was a phase II randomized trial: stage 1 was a 16-week treatment period, and stage 2 comprised 36-week treatment and 8-week follow-up periods. The primary endpoint was the proportion of patients with a validated Investigator Global Assessment Scale for AD score of 0 or 1 (vIGA 0/1) and ≥ 2-point reduction from baseline at week 16. Overall, 330 patients were randomized 2 : 1 double-blind to receive subcutaneous rademikibart 600 mg on day 1 and 300 mg Q2W from week 2-14, or placebo. Predose at week 16, patients were assessed for minimal important change [≥ 50% improvement from baseline in Eczema Area and Severity Index score (EASI 50)] and rerandomized 1 : 1 double-blind to rademikibart 300 mg Q2W or Q4W. RESULTS: In stage 1, 29.0% of patients attained vIGA 0/1 and ≥ 2-point reduction with rademikibart Q2W (P < 0.001) at week 16, without plateauing, vs. 5.9% with placebo. Rapid, significant improvements were also observed with all other rating scales in stage 1, including ≥ 75% improvement from baseline in EASI (EASI 75) (58.6% vs. 22.6%) and ≥ 4-point reduction in Peak Pruritus Numeric Rating Scale (PP-NRS) (36.3% vs. 10.5%) with rademikibart Q2W vs. placebo, respectively, at week 16. In stage 2, week 16 EASI 50 responders from stage 1 continued to improve through week 52 when treated with rademikibart Q2W or Q4W, including vIGA response (Q2W 59.1%; Q4W 62.6%), EASI 75 (Q2W 84.6%; Q4W 84.8%), and ≥ 4-point reduction in PP-NRS (Q2W 60.4%; Q4W 70.3%). Most patients with improvements during rademikibart Q2W therapy at week 16 maintained these responses through week 52 in both the rademikibart Q2W and Q4W groups: vIGA (Q2W 78.0%; Q4W 87.1%), EASI 75 (Q2W 90.1%; Q4W 92.3%) and ≥ 4-point reduction in PP-NRS (Q2W 85.3%; Q4W 94.8%). Injection site reactions were grade 1 (mild). No serious treatment-emergent adverse events (TEAEs) were treatment related. Three patients discontinued rademikibart owing to TEAEs (AD flare, vitiligo, pregnancy). CONCLUSIONS: Rademikibart Q2W induced rapid improvements in AD lesions and pruritus during the initial 16 weeks, which were maintained/improved further with rademikibart Q2W or Q4W across an additional 36 weeks. Rademikibart Q2W and Q4W were similarly efficacious and well tolerated. These findings are compatible with those from the published international phase II rademikibart trial, CBP-201-WW001. Atopic dermatitis (AD) is a common type of eczema, which can affect people of any age. People with moderate-to-severe AD can experience very sore and itchy skin. In some cases, they can develop depression and other mental health conditions. As the impact of eczema can be so deep, we need new medications that are effective and convenient to use. We carried out this clinical trial in China. We investigated a possible new medication, rademikibart, in adults and adolescents with moderate-to-severe AD. There were 330 participants in the trial, who were treated for 1 year. Stage 1 lasted 16 weeks. Participants received either rademikibart or a placebo (an inactive lookalike drug). The drug or placebo was injected every 2 weeks through week 14. Stage 2 was from week 16. Participants received rademikibart either every 2 weeks or every 4 weeks. We found that most participants had great improvements in their AD during treatment with rademikibart. Their AD symptom improvements happened quickly, in the first few days and weeks. Improvements continued across 1 year of treatment. No serious adverse events were treatment related. Three patients did discontinue rademikibart due to adverse events: an AD flare, vitiligo (white patches on the skin) or pregnancy. In our trial, AD symptoms improved for most participants during long-term treatment with rademikibart. This included relief from itching. Importantly, people had large improvements with rademikibart given once every 4 weeks, a convenient interval. However, a larger clinical trial is needed to further investigate rademikibart.
引用
- Zhang J, Silverberg JI, Guo J, et al. Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized phase II trial (SEASIDE CHINA): initial 2-week dosing, followed by 2-week or 4-week dosing. Br J Dermatol. 2026. PMID: 40892481. doi:10.1093/bjd/ljaf347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。